Increasing Life Expectancy in Cystic Fibrosis: Advances and Challenges

Overview

Journal Pediatr Pulmonol

Specialties Pediatrics
Pulmonary Medicine

Date 2021 Oct 21

PMID 34672432

Citations 51

Authors

Kimberly A McBennett

Pamela B Davis

Michael W Konstan

Affiliations

Soon will be listed here.

Abstract

Since the first description of cystic fibrosis in 1938, there have been significant advances in both quality of life and longevity for people living with this disease. In this article we describe the milestones of the last 80 years and what we perceive to be the remaining barriers to normalcy for this population.

Citing Articles

Hypogonadism in a Man With Cystic Fibrosis and an Unusually Low Serum Testosterone: A Cautionary Tale.

Lertdetkajorn K, Cobb C, Kapolka R, Hunt W, Tangpricha V AACE Clin Case Rep. 2025; 11(1):32-35.

PMID: 39896950 PMC: 11784604. DOI: 10.1016/j.aace.2024.09.008.

Anesthetic Management and Considerations for Cesarean Delivery in a Patient With Cystic Fibrosis.

Pham R, Mehdizadeh C, Baker C, Soloniuk L, Pasca I, Sinha A Case Rep Anesthesiol. 2025; 2025:6388254.

PMID: 39881848 PMC: 11774568. DOI: 10.1155/cria/6388254.

A Global Perspective on Transition Models for Pediatric to Adult Cystic Fibrosis Care: What Has Been Made So Far?.

Poamaneagra S, Plesca D, Tataranu E, Marginean O, Nemtoi A, Mihai C J Clin Med. 2024; 13(23).

PMID: 39685886 PMC: 11642410. DOI: 10.3390/jcm13237428.

Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders.

Amati F, Leonardi G, Contarini M, Morlacchi L, Stainer A, Pizzamiglio G Ther Adv Respir Dis. 2024; 18():17534666241253945.

PMID: 39582115 PMC: 11189011. DOI: 10.1177/17534666241253945.

Genomic and phenotypic characterization of isolates from two Mexican cystic fibrosis attention centers.

Nunez-Garcia L, Feliciano-Guzman J, Mireles-Davalos C, Lopez-Santiz J, Ovando-Fonseca J, Becerril-Vargas E Microbiol Spectr. 2024; :e0110024.

PMID: 39440985 PMC: 11619361. DOI: 10.1128/spectrum.01100-24.

References

Wainwright C, Elborn J, Ramsey B, Marigowda G, Huang X, Cipolli M . Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015; 373(3):220-31. PMC: 4764353. DOI: 10.1056/NEJMoa1409547. View

Flume P, Fischer Biner R, Downey D, Brown C, Jain M, Fischer R . Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021; 9(7):733-746. DOI: 10.1016/S2213-2600(20)30510-5. View

Sood N, Paradowski L, Yankaskas J . Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med. 2001; 163(2):335-8. DOI: 10.1164/ajrccm.163.2.2003076. View

Accurso F, Sontag M, Wagener J . Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr. 2005; 147(3 Suppl):S37-41. DOI: 10.1016/j.jpeds.2005.08.034. View

Kamal N, Surana P, Koh C . Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2018; 34(3):146-151. PMC: 7232742. DOI: 10.1097/MOG.0000000000000432. View

Yeung J, Machuca T, Chaparro C, Cypel M, Stephenson A, Solomon M . Lung transplantation for cystic fibrosis. J Heart Lung Transplant. 2020; 39(6):553-560. DOI: 10.1016/j.healun.2020.02.010. View

Farrell P, White T, Derichs N, Castellani C, Rosenstein B . Cystic Fibrosis Diagnostic Challenges over 4 Decades: Historical Perspectives and Lessons Learned. J Pediatr. 2017; 181S:S16-S26. DOI: 10.1016/j.jpeds.2016.09.067. View

Rho J, Ahn C, Gao A, Sawicki G, Keller A, Jain R . Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Am J Respir Crit Care Med. 2018; 198(8):1055-1063. PMC: 6221571. DOI: 10.1164/rccm.201711-2357OC. View

Maqbool A, Stallings V . Update on fat-soluble vitamins in cystic fibrosis. Curr Opin Pulm Med. 2008; 14(6):574-81. DOI: 10.1097/MCP.0b013e3283136787. View

10.

Oud L . Critical illness among adults with cystic fibrosis in Texas, 2004-2013: Patterns of ICU utilization, characteristics, and outcomes. PLoS One. 2017; 12(10):e0186770. PMC: 5655478. DOI: 10.1371/journal.pone.0186770. View

11.

Sergeev V, Chou F, Lam G, Hamilton C, Wilcox P, Quon B . The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Ann Am Thorac Soc. 2019; 17(2):147-154. PMC: 6993798. DOI: 10.1513/AnnalsATS.201909-671CME. View

12.

Shteinberg M, Taylor-Cousar J . Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur Respir Rev. 2020; 29(155). PMC: 9488599. DOI: 10.1183/16000617.0112-2019. View

13.

Flume P, Mogayzel Jr P, Robinson K, Rosenblatt R, Quittell L, Marshall B . Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010; 182(3):298-306. DOI: 10.1164/rccm.201002-0157OC. View

14.

Remmington T, Jahnke N, Harkensee C . Oral anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2016; 7:CD005405. PMC: 6457863. DOI: 10.1002/14651858.CD005405.pub4. View

15.

Rosenfeld M, Wainwright C, Higgins M, Wang L, McKee C, Campbell D . Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018; 6(7):545-553. PMC: 6626762. DOI: 10.1016/S2213-2600(18)30202-9. View

16.

di SantAgnese P, DARLING R, PERERA G, Shea E . Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics. 1953; 12(5):549-63. View

17.

Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994; 331(10):637-42. DOI: 10.1056/NEJM199409083311003. View

18.

Nichols A, Davies J, Jones D, Carr S . Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. Paediatr Respir Rev. 2020; 35:99-102. DOI: 10.1016/j.prrv.2020.04.003. View

19.

Floto R, Olivier K, Saiman L, Daley C, Herrmann J, Nick J . US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2015; 71 Suppl 1:i1-22. PMC: 4717371. DOI: 10.1136/thoraxjnl-2015-207360. View

20.

Schrijver I, Pique L, Graham S, Pearl M, Cherry A, Kharrazi M . The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostic Testing. J Mol Diagn. 2015; 18(1):39-50. DOI: 10.1016/j.jmoldx.2015.07.005. View